The purpose of this project is to determine the objective clinical response rate of TIL therapy in HPV-positive cancers and to investigate the specificity, phenotype, and function of TIL from HPV-positive cancers in vitro and in vivo. Our laboratory has established the feasibility of generating TIL from HPV-positive cancers at clinical grade and scale. Based on that work we have initiated a clinical trial of TIL from HPV-positive cancers (HPV-TIL) with the primary end point of objective clinical response rate. The trial is open to accrual at this time. Laboratory studies to characterize HPV-TIL and to innovate the next generate of cellular therapies for this family of diseases are ongoing.
|Hinrichs, Christian S (2016) Molecular Pathways: Breaking the Epithelial Cancer Barrier for Chimeric Antigen Receptor and T-cell Receptor Gene Therapy. Clin Cancer Res 22:1559-64|
|StevanoviÄ‡, Sanja; Draper, Lindsey M; Langhan, Michelle M et al. (2015) Complete regression of metastatic cervical cancer after treatment with human papillomavirus-targeted tumor-infiltrating T cells. J Clin Oncol 33:1543-50|
|Hinrichs, Christian S; Rosenberg, Steven A (2014) Exploiting the curative potential of adoptive T-cell therapy for cancer. Immunol Rev 257:56-71|